PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy
01-Jun-2015 -
NetScientific notes that portfolio company, PDS Biotechnology Corp., has announced positive preliminary data showing that its lead cancer immunotherapy treatment, PDS0101, has generated strong T-cell responses in pre-cervical cancer. Currently, pre-cervical cancer is treated by surgical removal ...
HPV
immunotherapeutics
T cells